PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33417512-0 2021 Berberine regulates the Notch1/PTEN/PI3K/AKT/mTOR pathway and acts synergistically with 17-AAG and SAHA in SW480 colon cancer cells. Berberine 0-9 mechanistic target of rapamycin kinase Homo sapiens 45-49 33428132-8 2020 Moreover, the results revealed the involvement of the mammalian target of rapamycin (mTOR) pathway in the induction of autophagy, and berberine could activate the phosphorylation of mTOR and thus mitigate autophagy. Berberine 134-143 mechanistic target of rapamycin kinase Homo sapiens 54-83 33428132-8 2020 Moreover, the results revealed the involvement of the mammalian target of rapamycin (mTOR) pathway in the induction of autophagy, and berberine could activate the phosphorylation of mTOR and thus mitigate autophagy. Berberine 134-143 mechanistic target of rapamycin kinase Homo sapiens 85-89 33428132-8 2020 Moreover, the results revealed the involvement of the mammalian target of rapamycin (mTOR) pathway in the induction of autophagy, and berberine could activate the phosphorylation of mTOR and thus mitigate autophagy. Berberine 134-143 mechanistic target of rapamycin kinase Homo sapiens 182-186 33417512-12 2021 BBR dose-dependently up-regulated PTEN, while inhibited Notch1, PI3K, Akt and mTOR proteins at 1.0-9.0 muM (p < 0.05). Berberine 0-3 mechanistic target of rapamycin kinase Homo sapiens 78-82 33362566-0 2020 Berberine Improves Chemo-Sensitivity to Cisplatin by Enhancing Cell Apoptosis and Repressing PI3K/AKT/mTOR Signaling Pathway in Gastric Cancer. Berberine 0-9 mechanistic target of rapamycin kinase Homo sapiens 102-106 34981469-9 2021 The expression levels of all tested genes were altered in all treatment groups compared to the control, with that of WNT1, CTNNB1, TCF, MTOR, AKT1, BIRC5, and CCND1 showing the most robust changes in the combined curcumin/berberine/5-FU treatment. Berberine 222-231 mechanistic target of rapamycin kinase Homo sapiens 136-140 33130557-6 2021 BBR treatment also antagonized mTOR activity, and was associated with increased recruitment of eIF4E-binding protein 1 (4E-BP1) in the translational complex, as revealed by m7-cap-binding assays, suggesting inhibition of cap-dependent translation. Berberine 0-3 mechanistic target of rapamycin kinase Homo sapiens 31-35 34643248-0 2021 Berberine exerts its antineoplastic effects by reversing the Warburg effect via downregulation of the Akt/mTOR/GLUT1 signaling pathway. Berberine 0-9 mechanistic target of rapamycin kinase Homo sapiens 106-110 34643248-8 2021 These findings indicated that the antineoplastic effect of BBR may involve the reversal of the Warburg effect by downregulating the Akt/mTOR/GLUT1 signaling pathway. Berberine 59-62 mechanistic target of rapamycin kinase Homo sapiens 136-140 33362566-10 2020 Mechanistically, berberine significantly suppressed the PI3K/AKT/mTOR in the BGC-823/DDP and SGC-7901/DDP cells treated with DDP. Berberine 17-26 mechanistic target of rapamycin kinase Homo sapiens 65-69 33362566-12 2020 Further mechanistic findings suggested that berberine-mediated DDP-sensitivity may be associated with reduced expression of drug transporters (multi-drug resistance-1 and multidrug resistance-associated protein 1), enhanced apoptosis and repressed PI3K/AKT/mTOR signaling. Berberine 44-53 mechanistic target of rapamycin kinase Homo sapiens 257-261 32682817-0 2020 Berberine and Emodin abrogates breast cancer growth and facilitates apoptosis through inactivation of SIK3-induced mTOR and Akt signaling pathway. Berberine 0-9 mechanistic target of rapamycin kinase Homo sapiens 115-119 32785222-11 2020 Berberine significantly reduced the expression level of mTOR mRNA (P = 0.001), and increased the expression level of IRS-1 mRNA (P = 0.009) in the PCOS granule cells. Berberine 0-9 mechanistic target of rapamycin kinase Homo sapiens 56-60 32682817-6 2020 Mechanistic studies further reveal that EMO and BBR in combined treatment inhibited SIK3-potentiated mTOR-mediated aerobic glycolysis and cell growth in breast cancer cells. Berberine 48-51 mechanistic target of rapamycin kinase Homo sapiens 101-105 32785222-14 2020 Berberine can improve the sensitivity of insulin by regulating the signal pathway of insulin receptor substrate-1 (IRS-1) and mammalian target of rapamycin (mTOR) in PCOS patients and achieve a therapeutic effect of treating PCOS. Berberine 0-9 mechanistic target of rapamycin kinase Homo sapiens 126-155 32785222-14 2020 Berberine can improve the sensitivity of insulin by regulating the signal pathway of insulin receptor substrate-1 (IRS-1) and mammalian target of rapamycin (mTOR) in PCOS patients and achieve a therapeutic effect of treating PCOS. Berberine 0-9 mechanistic target of rapamycin kinase Homo sapiens 157-161 32454290-0 2020 Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt signaling pathways. Berberine 0-9 mechanistic target of rapamycin kinase Homo sapiens 130-134 31926252-0 2020 Berberine mitigates high glucose-induced podocyte apoptosis by modulating autophagy via the mTOR/P70S6K/4EBP1 pathway. Berberine 0-9 mechanistic target of rapamycin kinase Homo sapiens 92-96 32394178-9 2020 Western blot showed that mammalian target of rapamycin (mTOR) signaling-related protein expressions, including phospho-mTOR, phospho-4EBP1, and phospho-p70 S6K (Thr389), but not phospho-p70 S6K (Ser371), were significantly increased in the TAC group, which were inhibited by berberine treatment. Berberine 275-284 mechanistic target of rapamycin kinase Homo sapiens 25-54 32394178-9 2020 Western blot showed that mammalian target of rapamycin (mTOR) signaling-related protein expressions, including phospho-mTOR, phospho-4EBP1, and phospho-p70 S6K (Thr389), but not phospho-p70 S6K (Ser371), were significantly increased in the TAC group, which were inhibited by berberine treatment. Berberine 275-284 mechanistic target of rapamycin kinase Homo sapiens 56-60 32184626-0 2020 Berberine Reverses Doxorubicin Resistance by Inhibiting Autophagy Through the PTEN/Akt/mTOR Signaling Pathway in Breast Cancer. Berberine 0-9 mechanistic target of rapamycin kinase Homo sapiens 87-91 32184626-8 2020 Mechanistically, we found that BBR inhibited autophagy by modulating the PTEN/Akt/mTOR signaling pathway. Berberine 31-34 mechanistic target of rapamycin kinase Homo sapiens 82-86 32454290-7 2020 Mechanistic studies showed that berberine inhibited mTOR, Akt and MAPK (ERK, JNK and p38) pathways thereby inducing autophagy. Berberine 32-41 mechanistic target of rapamycin kinase Homo sapiens 52-56 32454290-10 2020 Furthermore, inhibition of autophagy reversed berberine down-regulated mTOR, Akt and MAPK. Berberine 46-55 mechanistic target of rapamycin kinase Homo sapiens 71-75 32454290-12 2020 Briefly, these results indicated that berberine repressed human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt, and provided a molecular basis for the treatment of gastric cancer. Berberine 38-47 mechanistic target of rapamycin kinase Homo sapiens 168-172 31926252-9 2020 Notably, silencing mTOR with siRNA augmented the inhibition of P70S6k and 4EBP1 phosphorylation, which was similar to the effect of berberine. Berberine 132-141 mechanistic target of rapamycin kinase Homo sapiens 19-23 31926252-10 2020 SIGNIFICANCE: Berberine activates podocyte autophagy by inhibiting the mTOR/P70S6K/4EBP1 signaling pathway, thereby alleviating podocyte apoptosis. Berberine 14-23 mechanistic target of rapamycin kinase Homo sapiens 71-75 30021340-11 2018 At the same time, berberine increased the activation of p-AMPK and inhibited the activation of p-mTOR induced by NaH2PO4. Berberine 18-27 mechanistic target of rapamycin kinase Homo sapiens 97-101 32445451-3 2020 The above actions of berberine may mainly depend on activating AMPK and its downstream targets such as mammalian target of rapamycin (mTOR), sirtuin1 (SIRT1) , nuclear factor erythroid-2 related factor-2 (Nrf2), nuclear factor-kappaB (NF-kappaB), phosphoinositide 3-kinase / protein kinase B (PI3K/Akt), nicotinamide adenine dinucleotide (NAD+ ), and p38 mitogen-activated protein kinase (p38 MAPK). Berberine 21-30 mechanistic target of rapamycin kinase Homo sapiens 103-132 32445451-3 2020 The above actions of berberine may mainly depend on activating AMPK and its downstream targets such as mammalian target of rapamycin (mTOR), sirtuin1 (SIRT1) , nuclear factor erythroid-2 related factor-2 (Nrf2), nuclear factor-kappaB (NF-kappaB), phosphoinositide 3-kinase / protein kinase B (PI3K/Akt), nicotinamide adenine dinucleotide (NAD+ ), and p38 mitogen-activated protein kinase (p38 MAPK). Berberine 21-30 mechanistic target of rapamycin kinase Homo sapiens 134-138 31841506-0 2019 Combination treatment of berberine and solid lipid curcumin particles increased cell death and inhibited PI3K/Akt/mTOR pathway of human cultured glioblastoma cells more effectively than did individual treatments. Berberine 25-34 mechanistic target of rapamycin kinase Homo sapiens 114-118 30021340-13 2018 CONCLUSION: It was concluded that berberine therapy reduced myocardial injury partly by reducing myocardial autophagy and apoptosis through the AMPK/mTOR pathway. Berberine 34-43 mechanistic target of rapamycin kinase Homo sapiens 149-153 29079630-0 2017 ERK-dependent mTOR pathway is involved in berberine-induced autophagy in hepatic steatosis. Berberine 42-51 mechanistic target of rapamycin kinase Homo sapiens 14-18 29565467-0 2018 Berberine decelerates glucose metabolism via suppression of mTOR-dependent HIF-1alpha protein synthesis in colon cancer cells. Berberine 0-9 mechanistic target of rapamycin kinase Homo sapiens 60-64 29565467-7 2018 In addition, mTOR signaling previously reported to regulate HIF-1alpha protein synthesis was further found to be suppressed by berberine. Berberine 127-136 mechanistic target of rapamycin kinase Homo sapiens 13-17 29565467-8 2018 Taken together, our results indicated that berberine inhibits overactive glucose metabolism of colon cancer cells via suppressing mTOR-depended HIF-1alpha protein synthesis, which provided not only a novel mechanism involved in berberine"s tumor-specific toxicity but also a theoretical basis for the development of berberine for colon cancer treatment. Berberine 43-52 mechanistic target of rapamycin kinase Homo sapiens 130-134 29565467-8 2018 Taken together, our results indicated that berberine inhibits overactive glucose metabolism of colon cancer cells via suppressing mTOR-depended HIF-1alpha protein synthesis, which provided not only a novel mechanism involved in berberine"s tumor-specific toxicity but also a theoretical basis for the development of berberine for colon cancer treatment. Berberine 228-237 mechanistic target of rapamycin kinase Homo sapiens 130-134 29565467-8 2018 Taken together, our results indicated that berberine inhibits overactive glucose metabolism of colon cancer cells via suppressing mTOR-depended HIF-1alpha protein synthesis, which provided not only a novel mechanism involved in berberine"s tumor-specific toxicity but also a theoretical basis for the development of berberine for colon cancer treatment. Berberine 228-237 mechanistic target of rapamycin kinase Homo sapiens 130-134 29537893-4 2018 Now we take further our research by evaluating the effect of berberine, quercetin, tyrosol, and ferulic acid on the mTOR/S6K1/4E-BP1 signaling, along with the existence of any synergistic effect between the following associations: berberine + tyrosol, tyrosol + ferulic acid, ferulic acid + quercetin. Berberine 61-70 mechanistic target of rapamycin kinase Homo sapiens 116-120 28063518-7 2017 Finally, the individual administration of berberine, quercetin, ferulic acid, and tyrosol resulted in a statistically significant increase in AMPK activation and mTOR inhibition, whereas their associated administration did not reveal a synergistic effect. Berberine 42-51 mechanistic target of rapamycin kinase Homo sapiens 162-166 25837881-4 2015 Moreover, berberine inhibited the Akt/mTOR/p70S6/S6 pathway in berberine-treated BGC-823 cells. Berberine 10-19 mechanistic target of rapamycin kinase Homo sapiens 38-42 27557493-0 2016 Berberine induces autophagy in glioblastoma by targeting the AMPK/mTOR/ULK1-pathway. Berberine 0-9 mechanistic target of rapamycin kinase Homo sapiens 66-70 26722438-0 2015 Berberine regulates proliferation, collagen synthesis and cytokine secretion of cardiac fibroblasts via AMPK-mTOR-p70S6K signaling pathway. Berberine 0-9 mechanistic target of rapamycin kinase Homo sapiens 109-113 26722438-4 2015 And then we detected the role of AMPK/mTOR signaling pathway in berberine treatment of cardiac fibroblasts. Berberine 64-73 mechanistic target of rapamycin kinase Homo sapiens 38-42 26722438-9 2015 Mechanistically, the phosphorylation level of AMPK was increased; and the phosphorylation levels of mTOR and p70S6K were decreased in berberine treatment group. Berberine 134-143 mechanistic target of rapamycin kinase Homo sapiens 100-104 26722438-10 2015 CONCLUSION: These results illustrated that the protective effects of berberine on cellular behaviors of cardiac fibroblasts were at least in part due to activate AMPK signaling pathway and downregulate mTOR/p70S6K signaling pathway. Berberine 69-78 mechanistic target of rapamycin kinase Homo sapiens 202-206 25769560-3 2015 In the present study, we examined the role of phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) and mammalian target of rapamycin (mTOR) in the protective effect of BBR on hepatic I/R-mediated apoptosis in rats. Berberine 173-176 mechanistic target of rapamycin kinase Homo sapiens 108-137 25769560-3 2015 In the present study, we examined the role of phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) and mammalian target of rapamycin (mTOR) in the protective effect of BBR on hepatic I/R-mediated apoptosis in rats. Berberine 173-176 mechanistic target of rapamycin kinase Homo sapiens 139-143 25837881-4 2015 Moreover, berberine inhibited the Akt/mTOR/p70S6/S6 pathway in berberine-treated BGC-823 cells. Berberine 63-72 mechanistic target of rapamycin kinase Homo sapiens 38-42 25128467-5 2014 Their phosphorylation-mediated cytoplasmic sequestration followed by degradation was prevented by berberine-induced downmodulation of the PI3K/Akt/mTOR pathway which promoted FoxO nuclear retention. Berberine 98-107 mechanistic target of rapamycin kinase Homo sapiens 147-151 25310356-4 2014 Recent research has demonstrated that berberine has anticancer activity against various types of cancer, mediated through the suppression of mammalian target of rapamycin (mTOR). Berberine 38-47 mechanistic target of rapamycin kinase Homo sapiens 141-170 25310356-4 2014 Recent research has demonstrated that berberine has anticancer activity against various types of cancer, mediated through the suppression of mammalian target of rapamycin (mTOR). Berberine 38-47 mechanistic target of rapamycin kinase Homo sapiens 172-176 25310356-7 2014 Moreover, the cells treated with the combination of the two agents exhibited significantly decreased protein levels of phosphorylated (p)-p70S6 kinase 1 (Thr389), the downstream effector of mTOR, compared with the cells treated with rapamycin or berberine alone. Berberine 246-255 mechanistic target of rapamycin kinase Homo sapiens 190-194 25310356-8 2014 Furthermore, overexpression of cluster of differentiation (CD) 147, a transmembrance glycoprotein associated with the anticancer effects of berberine, was found to upregulate p-mTOR expression and inhibit cell death in SMMC7721 cells co-treated with rapamycin and berberine. Berberine 140-149 mechanistic target of rapamycin kinase Homo sapiens 177-181 25310356-8 2014 Furthermore, overexpression of cluster of differentiation (CD) 147, a transmembrance glycoprotein associated with the anticancer effects of berberine, was found to upregulate p-mTOR expression and inhibit cell death in SMMC7721 cells co-treated with rapamycin and berberine. Berberine 264-273 mechanistic target of rapamycin kinase Homo sapiens 177-181 25310356-9 2014 In conclusion, the findings of the present study suggest that the combined use of rapamycin and berberine may improve HCC therapy through synergistically inhibiting the mTOR signaling pathway, which is at least in part, mediated through CD147. Berberine 96-105 mechanistic target of rapamycin kinase Homo sapiens 169-173 24508518-7 2014 Moreover, berberine significantly inhibited the upstream signaling of autophagy, such as the mammalian target of rapamycin (mTOR), extracellular signal-regulated kinase (ERK1/2), and p38 mitogen-activated protein kinase (MAPK) phosphorylation. Berberine 10-19 mechanistic target of rapamycin kinase Homo sapiens 93-122 24508518-7 2014 Moreover, berberine significantly inhibited the upstream signaling of autophagy, such as the mammalian target of rapamycin (mTOR), extracellular signal-regulated kinase (ERK1/2), and p38 mitogen-activated protein kinase (MAPK) phosphorylation. Berberine 10-19 mechanistic target of rapamycin kinase Homo sapiens 124-128 20830746-6 2010 Berberine may also induce autophagic cell death in HepG2 and MHCC97-L cells through activation of Beclin-1 and inhibition of the mTOR-signaling pathway by suppressing the activity of Akt and up-regulating P38 MAPK signaling. Berberine 0-9 mechanistic target of rapamycin kinase Homo sapiens 129-133 20830746-7 2010 This is the first study to describe the role of Beclin-1 activation and mTOR inhibition in berberine-induced autophagic cell death. Berberine 91-100 mechanistic target of rapamycin kinase Homo sapiens 72-76